Entities / Company
Sanofi.
company in Milan, Italy
- Reports this week
- 0
- Active events
- 1
- Connections
- 120
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
One to three months ago
-
Sanofi collaborated on original report with US entities.Some support1 report
-
Sarclisa receives EMA approval for multiple myeloma, Sanofi develops new treatments, and Trump-era tariffs benefit AI stocks.Some support2 reports
-
Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.Well supported5 reports2 developments inside
-
Regeneron and Sanofi are seeking FDA approval for EYLEA HD pre-filled syringe and discussing collaboration expansion.Some support1 report
-
CEO Belén Garijo leads Sanofi through a strategic review.Some support1 report
-
Teva partners with Sanofi for Duvakitug development.Well supported5 reports
-
Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader.Some support4 reports2 developments inside
-
Elizabeth Laws has been appointed to lead the KT-621 development program, which is advancing as a first-in-class oral small molecule degrader, involving Sanofi and Kymera Therapeutics.Some support1 report
-
A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.Some support1 report1 development inside
Gone quiet
No new reports in 90+ days-
The Shapiro administration invested $10.6 million in Sanofi's technology, a company known for producing flu vaccines and buying eggs.Some support1 report
-
Analyst ratings are influencing stock price targets for Sanofi and Deutsche Bank.Some support1 report
-
Sanofi provided a $7 million milestone payment related to an agreement for upgrading a therapeutic development platform.Well supported4 reports1 development inside
-
Sanofi gained marketing authorization for its product Wayrilz in Japan on June 23, 2026.Some support1 report
-
The competitive landscape heats up as Sanofi's Dupixent faces challenges from AbbVie's new drug and Zumilokibart.Some support1 report
-
Developments include Roche and Genentech rolling out phenomaps, a partnership between Gibson and MIT, an MIT/Nvidia platform collaboration, and a Sanofi milestone achievement.Some support2 reports2 developments inside
-
Kardigan licensed a lead drug from Bristol-Myers Squibb, utilizing technology further developed by Mayo Clinic, while studying ataciguat originating at Sanofi.Some support1 report
-
Morgan Stanley initiated coverage and assigned ratings to Recursion Pharmaceuticals, Absci, and Schrodinger, while Recursion maintained partnerships with Sanofi and Bayer.Some support3 reports
-
Sanofi received orphan designation from the European Medicines Agency (EMA).Well supported3 reports
-
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Some support2 reports12 developments inside
-
Market growth in the health technology sector is being driven by advanced technology and policy changes involving major pharmaceutical companies.Speculative1 report
-
Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.Some support1 report1 development inside
-
Viatris stock significantly underperformed SPX and peer Sanofi on June 24, 2025.Speculative1 report
-
Teva plans to launch Austedo in European markets and partnered with Sanofi for duvakitug.Some support1 report1 development inside
-
The Health Sciences Authority (HSA) approved Beyfortus from both Sanofi and AstraZeneca for use in infants.Some support2 reports1 development inside
-
Sanofi and AstraZeneca announced a partnership regarding the drug Beyfortus.Speculative1 report
-
Sanofi is actively pursuing expanded drug approval in Europe and planning necessary regulatory filings in the United States.Speculative1 report
-
Sanofi advances Kymera's degrader candidate.Speculative1 report
-
Sanofi will advance Kymera Therapeutics into clinical testing.Speculative1 report
-
Sanofi is supporting local nonprofits across Massachusetts and funding initiatives involving Harvard College.Speculative1 report
-
Sanofi announced its results from Paris, France, on June 30, 2025, listing Timothy Gilbert, Nathalie Pham, and Yun Li as contacts.Speculative1 report
-
Adagene Inc. announced strategic developments regarding its ADG126 therapy, including FDA alignment, a partnership with Sanofi, and collaboration with Merck's anti-PD-1 therapy.Some support1 report2 developments inside
-
Sanofi representative announced to join Adagene’s Scientific Advisory Board.Speculative1 report
-
Sanofi received orphan designation in Japan and presented clinical trial data in Edinburgh.Speculative2 reports
-
FDA granted orphan drug designation to Sanofi's drug on July 6, 2025.Speculative2 reports
-
Several major pharmaceutical companies, including Pfizer, Amgen, Sanofi, and AstraZeneca, are leading the market for dyslipidemia treatments.Some support1 report1 development inside
-
Sanofi extended a license for its STAT6 program, while the FDA cleared an IND application for an IRAK4 degrader, and Gilead initiated a Phase 1 trial collaboration.Some support1 report
-
Market players, including Sanofi, Amgen, AstraZeneca, and GlaxoSmithKline, are noted for innovating to maintain competitiveness.Some support1 report
-
Market growth driven by Fabry disease treatment demand involving Amicus Therapeutics and Sanofi.Some support1 report
-
Sanofi acquired Blueprint for $9.5 billion, adding rare disease portfolio to its business.Well supported3 reports
-
Access to Advanced Health Institute, AstraZeneca, Moderna, University of Texas Medical Branch, Pfizer, and Sanofi were involved in nucleic acid-based vaccine projects as of August 7, 2025.Some support1 report1 development inside
-
Sanofi acquired Vicebio Ltd to expand its vaccine design capabilities.Some support1 report
-
Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.Some support1 report1 development inside
-
Alvotech, Dr. Reddy’s, Sanofi, and ALK-Abelló announced expanded partnerships and product launches in India.Some support1 report
-
Sanofi's GMMG-HD7 study was noted as being German-speaking in July 2025.Some support1 report
-
Sanofi's acquisition was featured in PR Newswire releases in July 2025.Some support1 report
-
Innate Pharma developed an mAb with AstraZeneca and is a trusted partner to Sanofi, with BTIG initiating analyst coverage.Some support2 reports
-
FDA approved Novavax's Nuvaxovid BLA, leading to Sanofi receiving a milestone payment and taking over U.S. commercial leadership.Well supported9 reports1 development inside
-
Novavax and Sanofi announced a partnership to facilitate vaccine access.Well supported3 reports
-
SAB BIO achieved FDA alignment on study design for the SAFEGUARD study, which is supported by strategic investment from Sanofi.Some support3 reports
-
Arrowhead received a milestone payment from Sarepta regarding their collaboration. Separately, Sanofi signed an asset purchase agreement with an Arrowhead subsidiary.Some support2 reports
-
Companies including Unilever, Intel, Sanofi, and Kenvue attended a supply chain innovation summit in August 2025.Some support1 report
-
Praluent, a drug, has limited availability in China.Some support1 report
-
Sanofi and ALX Oncology announced a partnership regarding a randomized Phase 1/2 clinical study.Some support1 report
-
LRN developed training courses for HP Inc., Sanofi, TE Connectivity, Standard Chartered, and Freeport-McMoRan.Some support1 report
-
TMO expanded a strategic partnership with Sanofi on August 28, 2025.Some support1 report
-
Thermo Fisher Scientific acquired Sanofi's factory on September 3, 2025.Well supported5 reports
-
Sanofi, Merck, and Pfizer are identified as key players in their respective markets.Some support2 reports
-
Sanofi's disappointing results cleared the way for Nektar Therapeutics.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Sanofi this week
News at the entities that move Sanofi most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Sanofi
-
Regeneron Pharmaceuticals OperationalRegeneron Pharmaceuticals and Wave Life Sciences are being compared as healthcare companies.Moves Sanofi
-
Food and Drug Administration StructuralIn 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Moves Sanofi
-
Toronto StructuralA multi-city food festival was held across Vancouver, Toronto, Calgary, and Victoria, featuring Michelin recognition in Toronto.Moves Sanofi
-
China StructuralThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Sanofi
-
Government of Canada StructuralThe Government of Canada has announced an investment in the Canadian Institutes of Health Research (CIHR) specifically dedicated to concussion research.Moves Sanofi
Connections
The 32 strongest of 120, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Regeneron Pharmaceuticals Operational
The two companies are engaged in a joint venture, co-developing and co-marketing the Dupixent eczema treatment, which includes shared revenues and royalty streams.
-
Novavax Structural
Novavax licensed its vaccine technology to Sanofi, which subsequently took over commercialization efforts and provided milestone payments.
-
Blueprint Structural
Sanofi acquired Blueprint, establishing it as a subsidiary and integrating its rare disease portfolio into Sanofi's operations.
-
Paul Hudson Structural
Paul Hudson serves as the CEO of Sanofi, holding a formal executive role that drives the company's strategy.
-
FDA Structural
The FDA formally evaluates, grants market access designations, and approves Sanofi's pharmaceutical products for use in the United States.
-
Kymera Therapeutics Structural
Kymera and Sanofi maintain a formal, ongoing partnership where Sanofi advances Kymera's drug candidates into clinical testing.
-
Blueprint Medicines (United States) Structural
Sanofi acquired Blueprint Medicines, establishing a parent-subsidiary relationship.
-
Belén Garijo Structural
Belén Garijo serves as the CEO, leading Sanofi through a strategic review.
Show all 32 connections
-
Bioverativ Structural
Bioverativ was acquired by Sanofi and operates as a subsidiary.
-
Government of Canada Structural
Sanofi and the Government of Canada have established a partnership involving a $925M investment in biomanufacturing.
-
AbbVie Operational
The companies are actively competing in the pharmaceutical market, evidenced by direct product rivalry and shared M&A pursuit.
-
Government of Ontario Operational
The two entities are engaged in a formal partnership regarding a $925M biomanufacturing investment.
-
Food and Drug Administration Structural
The FDA formally regulates and approves pharmaceutical products manufactured by Sanofi.
-
AstraZeneca Operational
Sanofi and AstraZeneca are actively collaborating on the production and scaling of the drug Beyfortus.
-
Thermo Fisher Scientific Inc. Structural
Thermo Fisher acquired Sanofi's manufacturing site and continues to produce therapies for Sanofi.
-
Toronto Structural
Sanofi operates a $925M flu vaccine manufacturing facility in Toronto.
-
China Structural
Sanofi's commercial operations and R&D efforts are structurally dependent on China's market and regulatory environment.
-
Amgen Operational
Sanofi and Amgen are direct competitors operating in the biopharma sector, vying for market leadership in dyslipidemia treatment.
-
Thermo Fisher Scientific (Netherlands) Transactional
Thermo Fisher acquired a sterile manufacturing factory site belonging to Sanofi.
-
Josh Shapiro Transactional
The Shapiro administration provided a $10.6 million investment in Sanofi's technology.
-
Morgan Stanley Operational
Morgan Stanley analysts influence Sanofi's market valuation through price target downgrades following clinical events.
-
Japan Operational
Sanofi gained marketing authorization for its product Wayrilz in Japan, establishing an operational presence in the market.
-
Cambridge Transactional
Sanofi agreed to acquire a biopharma firm located in Cambridge, Massachusetts.
-
Mélanie Joly Structural
Mélanie Joly provided federal government support enabling Sanofi's expansion.
-
Paulo Fontoura Structural
Paulo Fontoura holds an R&D head position at Sanofi.
-
Akeso Mentioned together
The entities are mentioned within a broader context discussing the growth trends of Chinese versus Western companies.
-
Kardigan Structural
Kardigan is involved in studying ataciguat, a compound that originated from Sanofi's research.
-
Biogen Shared context
Both Sanofi and Biogen operate within the biopharmaceutical sector, specifically targeting Alzheimer's treatment.
-
ANI Transactional
ANI's entity, Kennect, provides services to Sanofi as a client.
-
Deutsche Bank Mentioned together
The relationship is characterized by the general market mechanism where analyst ratings influence stock price targets.
-
Doug Ford Structural
The relationship is characterized by the government entity led by Doug Ford providing formal provincial support for Sanofi's expansion plans.
-
Pennsylvania Mentioned together
Evidence is insufficient to establish a link between Pennsylvania and Sanofi.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
2 eventsJuly 2026
3 events- Regeneron and Sanofi are seeking FDA approval for EYLEA HD pre-filled syringe and discussing collaboration expansion.
- CEO Belén Garijo leads Sanofi through a strategic review.
- Elizabeth Laws has been appointed to lead the KT-621 development program, which is advancing as a first-in-class oral small molecule degrader, involving Sanofi and Kymera Therapeutics.
Show 1 earlier month
June 2026
54 events- Sarclisa receives EMA approval for multiple myeloma, Sanofi develops new treatments, and Trump-era tariffs benefit AI stocks.
- Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.
- Teva partners with Sanofi for Duvakitug development.
- Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader.
- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
- The Shapiro administration invested $10.6 million in Sanofi's technology, a company known for producing flu vaccines and buying eggs.
- Analyst ratings are influencing stock price targets for Sanofi and Deutsche Bank.
- Sanofi provided a $7 million milestone payment related to an agreement for upgrading a therapeutic development platform.
- Sanofi gained marketing authorization for its product Wayrilz in Japan on June 23, 2026.
- The competitive landscape heats up as Sanofi's Dupixent faces challenges from AbbVie's new drug and Zumilokibart.
- Developments include Roche and Genentech rolling out phenomaps, a partnership between Gibson and MIT, an MIT/Nvidia platform collaboration, and a Sanofi milestone achievement.
- Kardigan licensed a lead drug from Bristol-Myers Squibb, utilizing technology further developed by Mayo Clinic, while studying ataciguat originating at Sanofi.
- Morgan Stanley initiated coverage and assigned ratings to Recursion Pharmaceuticals, Absci, and Schrodinger, while Recursion maintained partnerships with Sanofi and Bayer.
- Sanofi received orphan designation from the European Medicines Agency (EMA).
- Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
- Market growth in the health technology sector is being driven by advanced technology and policy changes involving major pharmaceutical companies.
- Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.
- Viatris stock significantly underperformed SPX and peer Sanofi on June 24, 2025.
- Teva plans to launch Austedo in European markets and partnered with Sanofi for duvakitug.
- The Health Sciences Authority (HSA) approved Beyfortus from both Sanofi and AstraZeneca for use in infants.
- Sanofi and AstraZeneca announced a partnership regarding the drug Beyfortus.
- Sanofi is actively pursuing expanded drug approval in Europe and planning necessary regulatory filings in the United States.
- Sanofi advances Kymera's degrader candidate.
- Sanofi will advance Kymera Therapeutics into clinical testing.
- Sanofi is supporting local nonprofits across Massachusetts and funding initiatives involving Harvard College.
- Sanofi announced its results from Paris, France, on June 30, 2025, listing Timothy Gilbert, Nathalie Pham, and Yun Li as contacts.
- Adagene Inc. announced strategic developments regarding its ADG126 therapy, including FDA alignment, a partnership with Sanofi, and collaboration with Merck's anti-PD-1 therapy.
- Sanofi representative announced to join Adagene’s Scientific Advisory Board.
- Sanofi received orphan designation in Japan and presented clinical trial data in Edinburgh.
- FDA granted orphan drug designation to Sanofi's drug on July 6, 2025.
- Several major pharmaceutical companies, including Pfizer, Amgen, Sanofi, and AstraZeneca, are leading the market for dyslipidemia treatments.
- Sanofi extended a license for its STAT6 program, while the FDA cleared an IND application for an IRAK4 degrader, and Gilead initiated a Phase 1 trial collaboration.
- Market players, including Sanofi, Amgen, AstraZeneca, and GlaxoSmithKline, are noted for innovating to maintain competitiveness.
- Market growth driven by Fabry disease treatment demand involving Amicus Therapeutics and Sanofi.
- Sanofi acquired Blueprint for $9.5 billion, adding rare disease portfolio to its business.
- Access to Advanced Health Institute, AstraZeneca, Moderna, University of Texas Medical Branch, Pfizer, and Sanofi were involved in nucleic acid-based vaccine projects as of August 7, 2025.
- Sanofi acquired Vicebio Ltd to expand its vaccine design capabilities.
- Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.
- Alvotech, Dr. Reddy’s, Sanofi, and ALK-Abelló announced expanded partnerships and product launches in India.
- Sanofi's GMMG-HD7 study was noted as being German-speaking in July 2025.
- Sanofi's acquisition was featured in PR Newswire releases in July 2025.
- Innate Pharma developed an mAb with AstraZeneca and is a trusted partner to Sanofi, with BTIG initiating analyst coverage.
- FDA approved Novavax's Nuvaxovid BLA, leading to Sanofi receiving a milestone payment and taking over U.S. commercial leadership.
- Novavax and Sanofi announced a partnership to facilitate vaccine access.
- SAB BIO achieved FDA alignment on study design for the SAFEGUARD study, which is supported by strategic investment from Sanofi.
- Arrowhead received a milestone payment from Sarepta regarding their collaboration. Separately, Sanofi signed an asset purchase agreement with an Arrowhead subsidiary.
- Companies including Unilever, Intel, Sanofi, and Kenvue attended a supply chain innovation summit in August 2025.
- Praluent, a drug, has limited availability in China.
- Sanofi and ALX Oncology announced a partnership regarding a randomized Phase 1/2 clinical study.
- LRN developed training courses for HP Inc., Sanofi, TE Connectivity, Standard Chartered, and Freeport-McMoRan.
- TMO expanded a strategic partnership with Sanofi on August 28, 2025.
- Thermo Fisher Scientific acquired Sanofi's factory on September 3, 2025.
- Sanofi, Merck, and Pfizer are identified as key players in their respective markets.
- Sanofi's disappointing results cleared the way for Nektar Therapeutics.